KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.
DALLAS, March 21, 2019 (GLOBE NEWSWIRE) — — via OTC PR WIRE
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company plans to publish its phase one research on the pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates.
The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies.
In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.
